Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5471713 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07332455Phase 2Recruiting
- Sponsor
- GSK
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 8
01
Overview
A Phase 2 trial of GSK5471713 in castration-resistant prostate cancer (CRPC), sponsored by GSK. Started Feb 2026; status: recruiting.
02
Drugs
GSK5471713
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07332455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332455.